

The promise of CD4⁺FoxP3⁺ regulatory T-cell manipulation *in vivo*: applications for allogeneic hematopoietic stem cell transplantation

Sabrina Copsel,^{1*} Dietlinde Wolf,^{2*} Krishna V. Komanduri^{1,2,3} and Robert B. Levy^{1,3,4}

¹Department of Microbiology and Immunology; ²Sylvester Comprehensive Cancer Center; ³Division of Transplantation and Cellular Therapy, Department of Medicine and ⁴Department of Ophthalmology, Miller School of Medicine, University of Miami, FL, USA

**SC and DW contributed equally to this work.*

©2019 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2018.198838

Received: February 4, 2019.

Accepted: May 7, 2019.

Pre-published: June 20, 2019.

Correspondence: ROBERT B. LEVY - rlevy@med.miami.edu

Supplemental Table 1. Clinical trials using IL-2 in GVHD. Trials listed at www.clinicaltrials.gov.

	Title	Identifier	Status	Results	Conditions	Locations
1	Prophylaxis Roles of IL-2 Treatment on Acute GVHD After Transplantation	NCT02659657	Recruiting	No results available	Acute GVHD	Peking University Institute of Hematology, Beijing, China
2	Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease	NCT01937468	Active, not recruiting	No results available	Chronic GVHD; Complications of Organ Transplant Stem Cells	<ul style="list-style-type: none"> Brigham and Women's Hospital Boston, Massachusetts, United States Dana-Farber Cancer Institute Boston, Massachusetts, United States
3	Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease	NCT00529035	Active, not recruiting	Has results	GVHD	<ul style="list-style-type: none"> Dana-Farber Cancer Institute Boston, Massachusetts, United States
4	Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease	NCT01366092	Active, not recruiting	Has results	Chronic GVHD	<ul style="list-style-type: none"> Dana-Farber Cancer Institute Boston, Massachusetts, United States Massachusetts General Hospital Boston, Massachusetts, United States Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

5	A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD	NCT02340676	Active, not recruiting	Has results	Chronic GVHD	<ul style="list-style-type: none"> Dana-Farber Cancer Institute Boston, Massachusetts, United States
6	In Vivo Treg Expansion and Graft-versus-Host-Disease Prophylaxis	NCT01927120	Completed	Has results	GVHD	<ul style="list-style-type: none"> H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
7	In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for Steroid-refractory Acute Graft-versus-Host-Disease (T-REG)	NCT01453140	Completed	No results available	GVHD	<ul style="list-style-type: none"> John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
8	Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation	NCT02226861	Completed	No results available	<ul style="list-style-type: none"> Acute Lymphoblastic Leukemia (ALL); Acute Myelogenous Leukemia (AML); Chronic Lymphocytic Leukemia (CLL); 	<ul style="list-style-type: none"> National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

					<ul style="list-style-type: none"> Chronic Myelogenous Leukemia (CML); MDS 	
9	<p>Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL-2 for GVHD (IL-2 for GVHD)</p> <hr/>	NCT00539695	Completed	Has results	<ul style="list-style-type: none"> Acute Lymphoblastic Leukemia (ALL); Acute Myelogenous Leukemia (AML); Chronic Myelogenous Leukemia (CML); Myelodysplastic Syndrome; Myeloproliferative Disorder; Hodgkin and Non-Hodgkin Lymphoma; 	<ul style="list-style-type: none"> Texas Children's Hospital Houston, Texas, United States The Methodist Hospital Houston, Texas, United States
10	<p>Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD</p> <hr/>	NCT02318082	Active, not recruiting	No results available	Chronic GVHD	<ul style="list-style-type: none"> Dana-Farber Cancer Institute Boston, Massachusetts, United States

11	Graft-versus-Host-Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease	NCT00003414	Completed	No results available	GVHD Lymphoma	<ul style="list-style-type: none">• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States
----	---	-------------	-----------	----------------------	---------------	---